Recurrent Campylobacter Bacteraemia in Immunocompromised Patients

Campylobacter Infections Clinical Trial

— CABARET  

Official title:

Recurrent Campylobacter Bacteraemia in Immunocompromised Patients: a Retrospective Nationwide Study in France, 2000-2025

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06432777
• Other study ID #: 69HCL24_0512
• Status: Not yet recruiting
• Start date: June 1, 2024
• Est. completion date: May 1, 2026

Study information

• Verified date: May 2024
• Source: Hospices Civils de Lyon
• Contact: Anne CONRAD, Dr
• Phone: +33 (0)4 72 07 11 07
• Email: Anne.conrad[@]chu-lyon.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Some rare cases of recurrent Campylobacter bacteraemia (RCB) exist with relapses months to years after an effective treatment and a negativation of all bacterial samples.

As of today, only around 20 cases have been described in the international literature for the last 30 years. The cases are likely highly underreported.

No study describes those recurrent Campylobacter bacteraemias at the scale of a country.

The aim of this multicentre, nationwide, retrospective study is to describe their precise epidemiology in France for the last 25 years, the immune profile of the patients, the specificities of the bacteria involved, the treatments received and the evolution of these infections.

The perspective is to propose a standardization of the medical care of those patients mainly by describing the effective treatments and the explorations of the immune system which should be considered.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: May 1, 2026
• Est. primary completion date: May 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 100 Years

Eligibility

Inclusion Criteria:

• 2 episodes or more of Campylobacter bacteraemia separated by at least 60 days

• AND immunodeficiency condition

• followed by a French hospital

Exclusion Criteria:

-Opposition of the patient

Related Conditions & MeSH terms

• Bacteremia
• Campylobacter Infections

Intervention

Other:
• Characteristics of patients and Campylobacter bacteraemia episodes
Variables: characteristics of the patients (demographic characteristics; characteristics of immunodeficiency: diagnosis, immunoglobulin dosage, white cells count etc.; chronic inflammatory bowel disease [IBD]), the bacteria (species, antimicrobial susceptibility) and the infection (clinical presentation, evolution, treatment received)

Locations

Country	Name	City	State
France	Infectious diseases department, Hospital de la Croix Rousse,	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Description of the characteristics of the patients presenting with recurrent Campylobacter bacteraemia	-demographic characteristics	Baseline
Primary	Description of the characteristics of the patients presenting with recurrent Campylobacter bacteraemia	-characteristics of immunodeficiency: diagnosis, immunoglobulin dosage, white cells count, polyvalent Ig replacement therapy	Baseline
Primary	Description of the characteristics of the patients presenting with recurrent Campylobacter bacteraemia	-chronic inflammatory bowel disease [IBD]	Baseline
Primary	Description of the characteristics of the patients presenting with recurrent Campylobacter bacteraemia	-characteristics of bacteraemia: clinical presentation, bacteria (species, antimicrobial susceptibility), secondary localizations, evolution, treatment modalities (antibiotics and immunother	Baseline